Inhaled corticosteroids and the risk of type 2 diabetes among Swedish COPD patients.
This study reports the association of ICS use and the risk of type 2 diabetes mellitus (T2DM) in Swedish patients with COPD using data from real-world, primary care settings. A total of 7078 patients with COPD were included in this analysis and the 5-year cumulative incidence rate per 100,000 person years was 1506.9. The yearly incidence rate per 100,000 person years ranged from 850 to 1919. Use of ICS especially at a high dose in patients with COPD was related to an increased risk of T2DM.
PMID: 33082331 [PubMed - in process]
Source: Primary Care - Category: Primary Care Authors: Ställberg B, Janson C, Lisspers K, Johansson G, Gutzwiller FS, Mezzi K, Bjerregaard BK, Kejs AMT, Jorgensen L, Larsson K Tags: NPJ Prim Care Respir Med Source Type: research
More News: Chronic Obstructive Pulmonary | Corticosteroid Therapy | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Primary Care | Study | Sweden Health